Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Receives Average Recommendation of “Hold” from Brokerages
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has received a consensus rating of “Hold” from the nine brokerages that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $56.40.
SUPN has been the topic of several analyst reports. BidaskClub downgraded shares of Walgreens Boots Alliance from a “sell” rating to a “strong sell” rating in a report on Monday, June 24th. Zacks Investment Research downgraded shares of H&E Equipment Services from a “hold” rating to a “sell” rating in a report on Wednesday, July 17th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $107.00 target price on shares of Perrigo in a report on Wednesday, May 8th. Finally, Mizuho reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, May 17th.
Several large investors have recently modified their holdings of the company. Raymond James & Associates raised its position in shares of Supernus Pharmaceuticals by 406.3% in the 4th quarter. Raymond James & Associates now owns 46,034 shares of the specialty pharmaceutical company’s stock worth $1,529,000 after acquiring an additional 36,942 shares in the last quarter. Advisor Group Inc. raised its position in shares of Supernus Pharmaceuticals by 17.2% in the 4th quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 306 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Supernus Pharmaceuticals by 8.1% in the 4th quarter. Geode Capital Management LLC now owns 588,259 shares of the specialty pharmaceutical company’s stock worth $19,541,000 after acquiring an additional 44,268 shares in the last quarter. Mackay Shields LLC bought a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth approximately $328,000. Finally, Brinker Capital Inc. raised its position in shares of Supernus Pharmaceuticals by 8.6% in the 4th quarter. Brinker Capital Inc. now owns 17,402 shares of the specialty pharmaceutical company’s stock worth $578,000 after acquiring an additional 1,379 shares in the last quarter. 99.29% of the stock is currently owned by institutional investors and hedge funds.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported $0.34 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.44 by ($0.10). Supernus Pharmaceuticals had a return on equity of 23.60% and a net margin of 25.49%. The business had revenue of $85.50 million for the quarter, compared to analysts’ expectations of $102.26 million. During the same period in the previous year, the business posted $0.49 earnings per share. The company’s revenue for the quarter was down 5.4% on a year-over-year basis. Research analysts anticipate that Supernus Pharmaceuticals will post 2.25 earnings per share for the current fiscal year.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
Further Reading: Bollinger Bands
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.